The drug Rwanda plans to roll out is the long-acting injectable Cabotegravir (CAB-LA), an intramuscular, long-acting form of PrEP. The first two injections are administered four weeks apart, followed ...
Piper Sandler analyst Jessica Tassan assigned a Buy rating to Omnicell (OMCL – Research Report) yesterday and set a price target of $69.00. The ...
According to Future Market Insights (FMI), the global asthma treatment market is poised for substantial growth, projected to hit USD 28.0 billion in 2024 and soar to USD 46.0 billion by 2034, with a ...
Although the reduction in the disparity gap was modest, the project is ongoing and appears to continue making progress.